Porch Group Announces a Renewed Partnership with Goosehead Insurance
SEATTLE--(BUSINESS WIRE)--Porch Group, Inc. ('Porch' or 'the Company') (NASDAQ: PRCH), a new kind of homeowners insurance company, announced today a renewed partnership with Goosehead Insurance ("Goosehead") (NASDAQ: GSHD).
Scaling Porch Reciprocal Exchange insurance premiums in a profitable manner is a key strategic priority for Porch. The renewed partnership with Goosehead represents a tangible step forward in the Company's efforts to re-activate agency partnerships and further extend its distribution channels.
'After a couple of years of managing premiums to roughly flat, the launch of the Porch Reciprocal Exchange at the start of 2025 marks the time where we have moved back to offense. Now as a high margin, commission and fee-based operator, we are thrilled to be growing premiums and leveraging our unique data to ensure better risk selection at the Reciprocal,' said Matt Ehrlichman, Founder and CEO of Porch Group. 'We have long considered Goosehead as both an important partner and an innovator in the industry, and we are excited to have the opportunity to deepen the relationship on a go-forward basis."
'We're renewing our partnership with Homeowners of America and expanding it to include the new Porch Insurance product,' said Mark Miller, President and CEO of Goosehead Insurance. 'This collaboration allows us to enhance product offerings for our clients, starting with the Porch Insurance product launch in Texas. By aligning our efforts, we're creating a path forward that should deliver unique home protection and innovative pricing solutions.'
About Porch Group
Porch Group, Inc. ('Porch') is a new kind of homeowners insurance company. Porch's strategy to win in homeowners insurance is to deploy leading vertical software solutions in select home-related industries, provide the best services for homebuyers including important moving services, leverage unique data for advantaged underwriting, and provide more protection for policyholders. To learn more about Porch, visit ir.porchgroup.com.
About Goosehead
Goosehead (NASDAQ: GSHD) is a rapidly growing and innovative independent personal lines insurance agency that distributes its products and services through corporate and franchise locations throughout the United States. Goosehead was founded on the premise that the consumer should be at the center of our universe and that everything we do should be directed at providing extraordinary value by offering broad product choice and a world-class service experience. Goosehead represents over 200 insurance companies that underwrite personal and commercial lines. For more information, please visit goosehead.com or goosehead.com/become-a-franchisee.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Jennifer Garner's baby food company confidentially files for an IPO, sources say
By Echo Wang and Abigail Summerville (Reuters) -Once Upon a Farm, the organic baby food company co-founded by actor Jennifer Garner, has filed confidentially for an initial public offering in New York, according to people familiar with the matter. The Berkeley, California-based company has tapped a group of investment banks for the IPO, which could occur as soon as this year, said the sources, who cautioned that the plans could change, depending on market conditions. Goldman Sachs and JPMorgan are the lead underwriters, said the sources, who requested anonymity because the plans are confidential. The offering could value the company at about $1 billion, one of the persons said. Once Upon a Farm did not immediately respond to a request for comment, Goldman Sachs and JPMorgan declined to comment. Garner is known for her work in the TV drama "Alias" and films including "Dallas Buyers Club" and "Catch Me If You Can." A mother of three, she has said she cares deeply about childhood nutrition, and she grows some produce for Once Upon a Farm on her family's century-old farm in Oklahoma. Once Upon a Farm was founded in 2015 by Cassandra Curtis and Ari Raz to create more nutritious baby-food options. In 2017, Garner and John Foraker, the former CEO of food brand Annie's, joined the company as co-founders. The company's products for babies, toddlers and children range from oat bars to cold-pressed pouches and frozen meals, and they are sold in supermarkets across the U.S. An IPO for the company would build on momentum for market debuts in the U.S., a sector that has lately thawed after the Trump administration's tariff announcements earlier this year cast a chill. So far this year, IPOs listed in the U.S. have raised about $27 billion, down from $41 billion in the same period last year, according to data compiled by Dealogic. But this year's figure is more than in 2022 and 2023, when IPOs raised $22 billion and $24 billion, respectively, over the same time frame, according to Dealogic. In its Nasdaq debut last week, digital bank Chime jumped 59%, valuing the company at $18.4 billion. The stock of stablecoin issuer Circle Internet Group climbed to $103.75 and was halted several times for volatility during a wild first day of trading earlier this month. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 minutes ago
- Business Wire
SINOVAC Board of Directors Files Definitive Proxy Materials
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with the filing of the definitive proxy statement, SINOVAC's Board of Directors mailed a letter to shareholders. In that letter, the SINOVAC Board urged valid shareholders to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. While a dissenting investor group led by Advantech/Prime Success and Vivo Capital (together known as the 'Dissenting Investor Group') is attempting to distract shareholders with false claims and empty promises as part of a hostile attempt to remove the SINOVAC Board and entrench themselves, the SINOVAC Board is committed to restoring fairness and delivering value to ALL SINOVAC shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Yahoo
14 minutes ago
- Yahoo
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions: Eyenovia's $50 Million PIPE to Acquire HYPE Tokens Chardan acted as sole placement agent in Eyenovia Inc.'s (NASDAQ: EYEN) $50 million PIPE financing. The proceeds are being used to acquire over 1 million HYPE tokens, the native asset of the Hyperliquid blockchain, making Eyenovia the first U.S.-listed company to hold HYPE in its treasury. This transaction positions Eyenovia as a top validator on the Hyperliquid network and includes a strategic staking initiative in partnership with Anchorage Digital. The financing involved the issuance of non-voting convertible preferred stock and warrants, potentially raising up to $150 million in total proceeds. Lion Group's $600 Million Facility to Launch Hyperliquid StrategyChardan acted as sole placement agent in Lion Group Holding's (NASDAQ: LGHL) $600 million facility. The facility supports the strategic accumulation of HYPE as a reserve asset, alongside Solana (SOL) and Sui (SUI). This represents LGHL's relaunch of crypto operations and its pivot toward decentralized finance infrastructure. VivoPower's $121 Million PIPE to Launch XRP Treasury StrategyChardan acted as placement agent for the $121 million private placement for VivoPower International PLC (NASDAQ: VVPR). VivoPower is believed to be the first public company to implement an XRP-focused digital asset treasury strategy. Proceeds will be used to acquire XRP, build out a decentralized finance team, and contribute to the XRPL ecosystem. Classover's $500 Million Convertible Notes for Solana Treasury Strategy Chardan served as financial advisor to Classover Holdings, Inc. (NASDAQ: KIDZ) in its $11 million initial tranche which is the first issuance under the $500 million senior secured convertible note financing. Under the terms of the financing agreement, approximately 80% of the net proceeds from the initial tranche will be allocated toward the purchase of Solana (SOL) tokens, subject to certain terms and limitations. Classover has already acquired over 6,400 SOL tokens and is exploring additional opportunities in staking and locked token acquisitions, reinforcing its commitment to blockchain-integrated financial strategy. Chardan's Vision for the Future of Finance "These transactions underscore our commitment to leading the convergence of traditional finance and digital assets," said Jonas Grossman, President and Managing Partner at Chardan. "We are proud to support visionary companies like Eyenovia, VivoPower, Classover, and Lion Group Holding as they redefine capital allocation and treasury management in the Web3 era." Chardan continues to expand its digital asset advisory capabilities, offering bespoke capital markets solutions, tokenomics structuring, and blockchain integration strategies for forward-thinking clients. About Chardan:Chardan is an independent global investment bank specializing in healthcare, digital assets, technology, SPACs, and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access, and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, and NASDAQ. Chardan Media Contact: Emily Levine Chief Commercial Officer elevine@ (475) 400-6071 View original content to download multimedia: SOURCE Chardan Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
